🔍

INDOCO - Indoco Remedies

📊 NSE: INDOCO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:02

📢 Recent Corporate Announcements

Indoco Remedies Schedules Q4 & FY26 Earnings Conference Call for May 07, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 27 Apr 2026, 03:47 PM

Indoco Remedies Limited has announced its earnings conference call to discuss the audited financial results for the quarter and full year ended March 31, 2026. The call is scheduled for Thursday, May 07, 2026, at 3:30 PM IST. Senior management, including the Managing Director, Joint Managing Director, and CFO, will be present to discuss performance and future outlook. This call follows the disclosure of the company's annual audited financial statements.

Earnings Conference Call scheduled for May 07, 2026, at 03:30 P.M. IST.
The call will cover audited financial results for the quarter and year ended March 31, 2026.
Management representation includes Ms. Aditi Panandikar (MD) and Mr. Pramod Ghorpade (CFO).
Universal dial-in numbers provided are +91 22 6280 1116 and +91 22 7115 8017.
The event is coordinated by Dolat Capital Market Pvt. Ltd.

💡 Investors should participate in the call to understand management's guidance on domestic growth and international regulatory updates. It is advisable to review the audited financial results once released before the call for detailed analysis.

Indoco Remedies Receives Zero Form 483 Observations from US FDA for Aurangabad Facility

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 13 Apr 2026, 06:47 PM

Indoco Remedies has successfully completed a US FDA Pre-Approval Inspection (PAI) at its testing facility in Chhatrapati Sambaji Nagar (Aurangabad). The inspection was conducted from April 08 to April 10, 2026, and concluded with zero Form 483 observations. This clean report signifies full compliance with US regulatory standards, which is a critical requirement for pharmaceutical exports to the United States. Such a positive outcome typically accelerates the approval process for new drug applications associated with this specific site.

US FDA inspection conducted at the Aurangabad testing facility from April 08 to April 10, 2026.
The inspection concluded with zero Form 483 observations, indicating no regulatory non-compliance.
This was a Pre-Approval Inspection (PAI), essential for the launch of new products in the US market.
Successful compliance reduces regulatory risk and strengthens the company's position in the US pharmaceutical sector.

💡 Investors should view this as a significant positive milestone that de-risks the company's US-facing operations. It is advisable to hold or monitor the stock for potential growth as new product approvals from this facility are likely to follow.

Indoco Remedies Submits Q4 FY26 Compliance Certificate Under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 02:22 PM

Indoco Remedies has filed its quarterly compliance certificate for the period ending March 31, 2026, as required under SEBI (Depositories and Participants) Regulations. The company's Registrar and Transfer Agent, MUFG Intime India Private Limited, confirmed that all dematerialization requests were processed within the stipulated timelines. The filing confirms that security certificates received were duly mutilated, cancelled, and the names of depositories were updated in the register of members. This is a standard procedural disclosure with no impact on the company's financial or operational performance.

Compliance certificate issued for the quarter ended March 31, 2026.
Registrar MUFG Intime India confirmed all demat requests were accepted or rejected as per norms.
Securities comprised in the certificates are listed on the relevant stock exchanges.
Verification and cancellation of physical certificates were completed within prescribed timelines.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial earnings for fundamental performance updates.

Indoco Remedies Re-appoints Cost and Internal Auditors for FY 2026-27

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Mar 2026, 01:25 PM

Indoco Remedies Limited has officially re-appointed its existing audit firms for the financial year 2026-2027. M/s Joshi Apte and Associates will continue as the Cost Auditors, while M/s. Suresh Surana & Associates LLP will remain the Internal Auditor. The decision was approved during a brief board meeting held on March 31, 2026, which lasted approximately 16 minutes. This move indicates a preference for continuity in the company's internal financial controls and cost auditing processes.

Re-appointment of M/s Joshi Apte and Associates as Cost Auditors for the 2026-2027 financial year.
Re-appointment of M/s. Suresh Surana & Associates LLP as Internal Auditors for the 2026-2027 financial year.
The board meeting for these approvals was conducted on March 31, 2026, between 01:00 p.m. and 01:16 p.m.
Compliance maintained under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 This is a routine administrative update and does not require any immediate action from investors. The continuity of auditors suggests stable internal governance and oversight.

Indoco Remedies Announces Trading Window Closure Starting April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 12:57 PM

Indoco Remedies Limited has officially announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's upcoming financial disclosures. The window will remain closed until 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results for the quarter and year ending March 31, 2026. The specific date for the board meeting to approve these results will be communicated at a later time.

Trading window closure effective from Wednesday, April 1, 2026.
Closure pertains to the Audited Standalone and Consolidated Financial Results for Q4 and FY 2025-26.
Restriction applies to all designated persons and their immediate relatives as per SEBI regulations.
The window will reopen 48 hours after the official announcement of the financial results.

💡 This is a routine regulatory filing and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to prepare for the Q4 and full-year earnings release.

Indoco Remedies to Participate in 11th Annual Valorem Conference on March 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:25 PM

Indoco Remedies Limited has scheduled a meeting with analysts and institutional investors on March 23, 2026. The senior management will participate in the 11th Annual Valorem Conference titled "Resilient Corporates, Relentless India" in Mumbai. The interaction is planned as a physical group meeting starting at 09:00 am at the Grand Hyatt, Santacruz. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction.

Participation in the 11th Annual Valorem Conference scheduled for March 23, 2026
Senior management to engage in group meetings with institutional investors and analysts
Physical interaction to take place at Grand Hyatt, Santacruz (East), Mumbai
Meeting organized by Valorem Advisors starting at 09:00 am
Company confirms no unpublished price sensitive information (UPSI) will be disclosed

💡 Investors should monitor for any post-conference investor presentations or transcripts that may provide qualitative insights into the company's growth outlook. No immediate trading action is required based on this routine disclosure.

Indoco Remedies Receives Final USFDA Approval for Brivaracetam Oral Solution

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Feb 2026, 11:50 AM

Indoco Remedies has secured final ANDA approval from the USFDA for Brivaracetam Oral Solution (10 mg/mL), a generic version of UCB's Briviact. This antiepileptic drug is used for treating partial-onset seizures in patients as young as 1 month old. The product will be manufactured at the company's USFDA-approved facility in Goa, India. This approval marks a significant milestone in Indoco's strategy to expand its presence in the high-value regulated US market.

Final USFDA approval received for Brivaracetam Oral Solution, 10 mg/mL
Generic equivalent to the reference listed drug Briviact by UCB, Inc.
Manufacturing to be conducted at the company's Goa facility (L-14, Verna Industrial Area)
Indoco maintains a global turnover of US$ 180 million with 10 manufacturing facilities
Target therapeutic area is antiepileptic treatment for patients 1 month and older

💡 Investors should monitor the commercial launch timeline and potential market share capture in the US generic market. This approval strengthens the company's export portfolio and could contribute to margin expansion in the upcoming quarters.

Indoco Remedies Q3 FY26: Cons. Revenue Up 7.9% YoY to ₹434 Cr; EBITDA Margins Expand to 7.3%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 09 Feb 2026, 05:58 PM

Indoco Remedies reported a 7.9% YoY increase in consolidated revenue to ₹4,343 million for Q3 FY26, supported by a 26.2% growth in international formulations. Consolidated EBITDA margins improved to 7.3% from 3% YoY, even after accounting for ₹8-9 crore in non-recurring remediation costs and penalties. While the domestic business remained flat due to pressure in acute therapies, the company improved its prescription ranking to 21st in IQVIA audits, surpassing Pfizer. The Patalganga API site successfully received a USFDA EIR with zero 483 observations, strengthening its regulatory profile.

Consolidated revenue grew 7.9% YoY to ₹4,343 million, while API business surged 24% to ₹344 million.
International formulations saw robust growth of 26.2% YoY, with Europe growing 36.9% and the US up 21.6%.
EBITDA margins expanded to 7.3% from 3% YoY, despite one-time remediation and penalty costs of approximately ₹8-9 crore.
The company reached the 21st rank in IQVIA prescription audits with a total of 10.86 crore prescriptions.
Patalganga API facility received USFDA EIR with zero 483 observations; Goa Plant II status remains under watch.

💡 Investors should monitor the recovery in the domestic acute segment and the resolution of USFDA issues at the Goa Plant II. The expansion in API and international margins is a positive sign for long-term profitability and operational efficiency.

Indoco Remedies Announces Conclusion of GST Search by Maharashtra Authorities

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 09 Feb 2026, 05:37 PM

Indoco Remedies Limited has reported the conclusion of a GST inspection and search by the Maharashtra State GST Department. The search, which was initiated around February 3, 2026, officially concluded on February 8, 2026, at 8:15 PM. The company has provided all requested documents and clarifications to the authorities during the process. Currently, no official order or demand notice has been issued, and the company maintains that there is no material impact on its financial or operational activities.

Maharashtra State GST Department concluded its search on February 8, 2026, at 20:15 IST.
The inspection was conducted under Section 67 of the Maharashtra Goods & Service Tax Act, 2017.
No official document or violation notice has been issued to the company following the search.
Management confirms no material impact on the company’s financials or operations due to this event.

💡 Investors should view this as a routine regulatory update since no financial demand has been raised yet. Continue to monitor for any future show-cause notices that may arise from the findings of this inspection.

Indoco Remedies Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 03 Feb 2026, 06:40 PM

Indoco Remedies has officially released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, conducted on February 3, 2026, provides management's perspective on the company's unaudited standalone and consolidated financial performance. This disclosure is part of the mandatory compliance under SEBI Listing Obligations and Disclosure Requirements. Investors can access the recording via the company's website to gain insights into operational trends and future guidance.

Earnings conference call conducted on February 3, 2026, following Q3 results.
Covers financial performance for the nine-month period ending December 31, 2025.
Recording made available on the company's official website under the investor section.
The call duration was approximately 58 minutes, concluding at 4:28 p.m. IST.
Compliance filing submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's commentary on margin pressures or growth drivers in the pharma sector. This is a routine update and does not contain new material financial data beyond what was in the earnings report.

Indoco Remedies Q3 Results: Consolidated Loss Widens to ₹29.45 Cr Amid Subsidiary Concerns

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 11:59 AM

Indoco Remedies reported a consolidated net loss of ₹29.45 crore for the quarter ended December 31, 2025, compared to a loss of ₹28.40 crore in the previous year. While consolidated revenue grew 8.5% YoY to ₹445.36 crore, the bottom line was hit by rising finance costs and an exceptional charge of ₹6.94 crore related to New Labour Code liabilities. A significant concern is the auditor's 'Emphasis of Matter' regarding two subsidiaries, FPP Holding LLC and Warren Remedies, which have substantial negative net worth and material uncertainty regarding their status as going concerns.

Consolidated revenue from operations rose 8.5% YoY to ₹445.36 crore in Q3FY26.
Reported a consolidated net loss of ₹29.45 crore for the quarter.
Exceptional loss of ₹6.94 crore recognized due to implementation of New Labour Codes affecting employee benefits.
Auditors flagged material uncertainty for subsidiaries FPP Holding LLC and Warren Remedies with a combined negative net worth exceeding ₹93 crore.
Finance costs increased significantly to ₹25.64 crore from ₹16.11 crore in the year-ago quarter.

💡 Investors should remain cautious due to persistent losses and the auditor's warning regarding the financial health of key subsidiaries. Monitor the company's ability to manage its rising finance costs and the turnaround strategy for its international operations.

Indoco Remedies Reports GST Search at Registered Office for FY 2020-21 Onwards

🔵 WATCH ⭐ 6/10

REGULATORY 📅 03 Feb 2026, 11:16 AM

GST authorities from the Maharashtra State GST Department conducted a search at Indoco Remedies' registered office on February 2, 2026. The inspection, carried out under Section 67 of the CGST and SGST Act, involves the verification of books of accounts for the period from 2020-2021 to the present. The company has stated that the proceedings are ongoing and they are cooperating fully with the authorities. As of now, no specific allegations have been made and no financial impact has been quantified.

Maharashtra State GST Department initiated search and seizure proceedings on February 2, 2026.
The investigation covers a five-year period of books of accounts from FY 2020-2021 to date.
Action taken under Section 67 of the CGST Act and SGST Act (Power to Inspect, Search and Seizure).
No specific violations or monetary demands have been communicated by the authorities so far.

💡 Investors should monitor future disclosures for any tax demands or penalties resulting from this search. While the search creates short-term uncertainty, the final impact will depend on the findings of the GST department.

Indoco Remedies Allots 55,700 Equity Shares Under ESOP 2022 Plan

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 09:38 AM

Indoco Remedies has approved the allotment of 55,700 equity shares to the Indoco Employees Welfare Trust under its 2022 ESOP scheme. The allotment consists of 42,300 shares at an exercise price of Rs. 307 and 13,400 shares at a face value price of Rs. 2. This transaction has increased the company's total paid-up equity capital to Rs. 18.46 crore. The total amount raised through this exercise is approximately Rs. 1.30 crore.

Allotment of 55,700 equity shares of face value Rs. 2 each approved on February 3, 2026
Total paid-up capital increased from 9,22,47,905 to 9,23,03,605 equity shares
Exercise prices were bifurcated into 42,300 shares at Rs. 307 and 13,400 shares at Rs. 2
Total capital infusion from the exercise amounts to Rs. 1,30,12,900

💡 This is a routine administrative matter with negligible equity dilution. No specific action is required from investors based on this announcement.

Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 30 Jan 2026, 01:23 PM

Indoco Remedies has received final ANDA approval from the USFDA for Lacosamide Oral Solution USP, 10 mg/mL, a generic version of UCB's Vimpat. The product is indicated for treating seizures in epilepsy patients aged 4 years and older. Manufacturing will take place at the company's Goa facility, supporting Indoco's global expansion strategy. With a current turnover of US$ 180 million, this approval adds a key product to Indoco's US portfolio.

Final ANDA approval granted for Lacosamide Oral Solution USP, 10 mg/mL
Generic equivalent to the Reference Listed Drug (RLD) Vimpat Oral Solution by UCB, Inc.
Product to be manufactured at the USFDA-approved facility in Verna, Goa
Indicated for partial onset and primary generalized tonic-clonic seizures
Indoco maintains a global turnover of US$ 180 million with 11 manufacturing facilities

💡 Investors should view this as a positive development that strengthens Indoco's US generic pipeline. Monitor the product's commercial launch and its contribution to the company's export revenue in the coming quarters.

Indoco Remedies to Host Q3FY26 Earnings Conference Call on February 3, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 20 Jan 2026, 11:44 AM

Indoco Remedies Limited has scheduled its earnings conference call to discuss the unaudited financial results for the third quarter and nine months ended December 31, 2025. The call is slated for Tuesday, February 3, 2026, at 3:30 PM IST and will be hosted by Nirmal Bang Institutional Equities. Key management personnel, including the Managing Director and CFO, will be present to address queries regarding the company's performance. This is a routine regulatory filing following the end of the reporting period.

Earnings call scheduled for February 3, 2026, at 3:30 PM IST
Focus on financial results for the quarter and nine months ended December 31, 2025
Management representation includes MD Aditi Panandikar and CFO Pramod Ghorpade
Call hosted in coordination with Nirmal Bang Institutional Equities

💡 Investors should mark the date to listen to management commentary on margin trends and growth outlook; no immediate action is required until results are published.

View All INDOCO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Domestic Formulations revenue was INR 2,261 Mn in Q2 FY26, a decline of 3.6% YoY. International Formulations grew 21.5% YoY to INR 1,533 Mn. API revenue surged 43% YoY to INR 431 Mn. Allied Services (CRO & IAS) grew 83.8% YoY to INR 68 Mn.

Geographic Revenue Split

Domestic business contributes 53% of standalone revenue. International markets contribute 36%, with the US at INR 336 Mn (up 36% YoY), Europe at INR 547 Mn (down 8.7% YoY), and Emerging Markets at INR 618 Mn (up 56% YoY).

Profitability Margins

Consolidated PAT margin was -2.0% in Q2 FY26 compared to -2.3% YoY. Standalone EBITDA margin stood at 12.4% in Q2 FY26, down from 13.4% YoY. H1 FY26 consolidated PAT margin was -5.0%.

EBITDA Margin

Consolidated EBITDA margin was 9.1% in Q2 FY26, a slight decrease from 9.3% in Q2 FY25. Standalone EBITDA margin for H1 FY26 was 8.4%, down from 13.2% YoY, primarily due to increased operating expenses and supply-side disruptions.

Capital Expenditure

The company is undergoing a Master Manufacturing Plan (MMP) involving significant refurbishment of manufacturing plants. While specific total INR Cr is not disclosed, these investments are intended to modernize facilities and address global pricing pressures.

Credit Rating & Borrowing

Long-term rating is [ICRA]A (Negative), downgraded from [ICRA]A+ (Negative). Short-term rating reaffirmed at [ICRA]A2+. Finance costs rose 38% YoY to INR 246 Mn in Q2 FY26 due to high debt levels (Net Debt to Equity of 0.68).

⚙️ Operational Drivers

Raw Materials

Key Starting Materials (KSMs) for API production and various packaging materials. Specific chemical names and their % of total cost are not disclosed in available documents.

Capacity Expansion

Current capacity includes 11 manufacturing facilities (7 FDF and 4 API). Planned expansion is focused on the Master Manufacturing Plan (MMP) refurbishment and the completion of finished product construction at the Warren Remedies API site.

Raw Material Costs

Profitability is vulnerable to fluctuations in raw material and packaging costs. Raw material costs are managed through the MMP to improve efficiency, though specific YoY % changes for raw materials are not disclosed.

Manufacturing Efficiency

Efficiency is currently impacted by plant refurbishments. The company aims to improve EBITDA returns in Europe and Emerging Markets through on-ground presence and branded business focus.

Logistics & Distribution

The company received the 'Next 5 (Top) Supply Chain & Logistics Award' from Alden Global Value Advisors, indicating recognized distribution capabilities.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved by expanding Indoco UK (launched Nov 2024), scaling the OTC/OTX business (Warren Remedies) which grew 40% YoY, and 'owning the chain' by buying back assets from partners like Teva to control launch timelines and margins.

Products & Services

Medicines (Domestic and International Formulations), Active Pharmaceutical Ingredients (APIs), and Allied Services including Clinical Research (CRO) and Analytical Solutions.

Brand Portfolio

Cyclopam, Oxipod, Febrex Plus, ATM, Cital, Atherochek, Vepazil, Tuspel AA, Braceness, Multifibro, and Toco Fibro.

New Products/Services

Launched 6 new products in Q2 FY26: Vepazil 250/500, Tuspel AA, Braceness Toothpaste, Multifibro Capsule, and Toco Fibro Capsule.

Market Expansion

Indoco UK will begin sales operations in Nov 2025 with 3 products. The company also signed multiple B2B deals across Eastern Europe in FY25 to expand its core portfolio reach.

Market Share & Ranking

Ranked 31st in the Indian Pharmaceutical Market (IPM) with a 0.56% market share and 20th in prescription ranking as of September 2025.

Strategic Alliances

Previously partnered with Teva; currently buying back assets to own future product launches. Strategic B2B partnerships are being pursued in Europe and Emerging Markets.

🌍 External Factors

Industry Trends

The European generic market is valued at Euro 103 billion, presenting a key focus area. There is a shift toward branded generics in Emerging Markets where Indoco is focusing on on-ground personnel.

Competitive Landscape

Key competitors include global generic players and local manufacturers in international markets. Indoco competes through high brand equity and customer trust.

Competitive Moat

Durable advantages include a 70-year legacy in India, a strong R&D focus on complex ophthalmics, and a top-20 ranking in prescription generation, which are sustainable through continued pipeline investment.

Consumer Behavior

Shift toward sub-chronic care and increased demand for OTC oral care products in the Indian market.

Geopolitical Risks

Vulnerable to trade barriers and stiff competition from low-priced generics and locally manufactured products in Emerging Markets.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by USFDA manufacturing standards and domestic pricing controls under the National List of Essential Medicines (NLEM).

⚠️ Risk Analysis

Key Uncertainties

Regulatory constraints at sterile manufacturing plants and supply-side disruptions from the Master Manufacturing Plan (MMP) refurbishment, which impacted H1 FY26 performance.